Anti-LIMA1 Antibody

The Lim domain and actin-binding protein 1 (LIMA1) is cytoskeleton-associated protein that inhibits actin filament depolymerization and cross-links filaments in bundles and is downregulated in some cancer cell lines (1,2) . LIMA1 is also a key molecule linking the cadherin-catenin complex to the actin cytoskeleton (3) . Recent studies have shown that EGF activates ERK1/2-dependent phosphorylation, ubiquitination and degradation of LIMA1, leading to increased invasiveness and metastasis of metastatic prostate cancer models (4) .

LIMA1 antibody was raised against an 18 amino acid peptide near the amino terminus of human LIMA1. The immunogen is located within amino acids 230 - 280 of LIMA1.

Highly expressed in placenta, kidney, pancreas, prostate, ovary, spleen and heart. Also detected in lung, liver, brain, skeletal muscle, thymus, testis and intestine. Not detected in leukocytes. Isoform Beta expressed generally at very low levels. Isoform Alpha abundant in epithelial cells from mammary gland, prostate and in normal oral keratinocytes. Low levels in aortic endothelial cells and dermal fibroblasts. Not detectable in myocardium.

Actin-binding protein involved in actin cytoskeleton regulation and dynamics. Increases the number and size of actin stress fibers and inhibits membrane ruffling. Inhibits actin filament depolymerization. Bundles actin filaments, delays filament nucleation and reduces formation of branched filaments (PubMed:12566430) . Plays a role in cholesterol homeostasis. Influences plasma cholesterol levels through regulation of intestinal cholesterol absorption. May act as a scaffold protein by regulating NPC1L1 transportation, an essential protein for cholesterol absorption, to the plasma membrane by recruiting MYO5B to NPC1L1, and thus facilitates cholesterol uptake (By similarity) .